Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 3,496.80% | -4.14% | |||
| Gross Profit | -3,496.80% | 4.14% | |||
| SG&A Expenses | 16.63% | -50.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.25% | -45.51% | |||
| Operating Income | 25.25% | 45.51% | |||
| Income Before Tax | 27.07% | 45.04% | |||
| Income Tax Expenses | 4,488.18% | 816.67% | |||
| Earnings from Continuing Operations | 16.00% | 44.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.00% | 44.91% | |||
| EBIT | 25.25% | 45.51% | |||
| EBITDA | 25.30% | 45.56% | |||
| EPS Basic | 19.57% | 60.10% | |||
| Normalized Basic EPS | 30.17% | 60.20% | |||
| EPS Diluted | 19.57% | 60.10% | |||
| Normalized Diluted EPS | 30.17% | 60.20% | |||
| Average Basic Shares Outstanding | 4.42% | 38.07% | |||
| Average Diluted Shares Outstanding | 4.42% | 38.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||